Tyler、TXにおけるクローン病の臨床試験
Tylerとその周辺地域（約30マイル以内）の拠点で、クローン病に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
被験者募集中第3相
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
被験者募集中第3相
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
被験者募集中第2相
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
被験者募集中第3相
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
被験者募集中第2/3相
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
被験者募集中第2相
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
被験者募集中第3相
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
被験者募集中第3相
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
被験者募集中第3相
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
被験者募集中第2相
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
被験者募集中第4相
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
被験者募集中第3相
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
被験者募集中第3相
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
被験者募集中第2相
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
被験者募集中第2相
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
被験者募集中第2相
- Mirador Therapeutics Selected Site, Tyler
他の都市におけるクローン病の試験
- New York City, NY35件の研究
- Cleveland, OH19件の研究
- St. Louis, MO19件の研究
- Boston, MA19件の研究
- Miami, FL19件の研究
- Orlando, FL17件の研究
- Houston, TX17件の研究
- Atlanta, GA17件の研究
- San Diego, CA15件の研究
- San Antonio, TX15件の研究
- Los Angeles, CA15件の研究
- Philadelphia, PA13件の研究
Tylerにおける他の研究
- 非小細胞肺癌20件の研究
- 潰瘍性大腸炎14件の研究
- 大腸癌8件の研究
- 心不全8件の研究
- がん（全種類）7件の研究
- 卵巣がん7件の研究
- 子宮内膜がん6件の研究
- 頭頸部扁平上皮癌6件の研究
- 乳がん6件の研究
- 転移性癌5件の研究
- 炎症性腸疾患5件の研究
- 慢性リンパ性白血病5件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。